Advertisement

Today’s Problems and Results of Biological Research in Schizophrenia

  • H. Hippius
  • M. Ackenheil

Abstract

Since 1908, since exactly 75 years ago, the usage of the term “group of schizophrenias” suggested by Eugen BLEULER for the endogenous psychoses for whose central group Emil KRAEPELIN coined the term “dementia praecox” in the 6th edition of his textbook in 1899, has become standard in psychiatry.

Keywords

Schizophrenic Patient Growth Hormone Secretion Beta Endorphin Neuroleptic Treatment Schizophrenic Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature

  1. M. Ackenheil, D. Athen, H. Beckmann: Pathophysiology of delirious states. J of Neural Transmission, Suppl. 14, 167–175 (1978)Google Scholar
  2. M. Ackenheil, H. Hippius, N. Matussek: Ergebnisse der biochemischen Forschung auf dem Schizophreniegebit. Der Nervenarzt 49, 634–649 (1978)PubMedGoogle Scholar
  3. M. Ackenheil, R. Engel: Stressuntersuchungen bei psychiatrischen Patienten. 75-Jahrfeier der Psychiatrischen Klinik der Universitäte München. Münchener Med Wschr, 123, No 19, 805–808 (1981)Google Scholar
  4. M. Ackenheil: Biochemical effects of apomorphine: contribution to schizophrenia research: apomorphine and other dopaminomimetics, VI 2, Clinical Pharmacol, 215–225, Raven Press N.W. Eds.: G. U. Corsini, G.L. Gessa (1981)Google Scholar
  5. M. Ackenheil, U. Münch, H. Wissmann: Die Bedeutung des Mienenspiels in der Psychiatrie. 99. Wander Versammlung süd westdeutscher Psychiater und Neurologen Baden-Baden, 1983.Google Scholar
  6. M. Albus, M. Ackenheil, U. Münche, D. Naber: Ceruletide: A new drug for the treatment of schizophrenic patients? Arch Gen Psychiatry, Vol 4, 528 (1984)CrossRefGoogle Scholar
  7. M. Ansseau, A. Doumont, 3.3. Legros: Evidence for two subgroups of schizophrenics with regard to dopaminergic sensitivity. 5th CA Symposium Göteborg 1983. Abstracts. Suppl to Progress in Neuro-Psychopharmacology and Biological Psychiatry, p 69Google Scholar
  8. B. Bondy, M. Ackenheil, R. Elbers, M. Fröhler: Binding of H-spiperone to human lymphocytes: a biological marker in schizophrenia? Accepted by Psychiatry Research 1984Google Scholar
  9. A. Carlsson, W. Kehr, M. Linquist: Receptor mediated control of dopamine- synthesis. In: Neuropsychopharmacology. Ed.: J. R. Boissier, H. Hippius, P. Pichot. American Elsevier Publ Comp Inc New York, pp 468–471 (1975)Google Scholar
  10. K. Conrad, W. Scheid, H. J. Weitbrecht: Die beginnende Schizophrenie. Versuch einer Gestaltanalyse des Wahns. Sammlung psychiatrischer und neurologischer Einzeldarstellungen. Georg Thieme Verlag, Stuttart (1958).Google Scholar
  11. I. Creese, D.R. Burt, S.H. Snyder: Dopamine receptor binding: Differentiation of agonist and antagonist states with H-dopamine and Haloperidol. Life Science 17, 993–1002 (1975)CrossRefGoogle Scholar
  12. A. J. Cross, T. J. Crow, A. Longden, F. Owen, M. Poulter, G.J. Riley: Evidence for increased dopamine receptor sensitivity in post mortem brains from patients with schizophrenia. J Physiol 290:456 (1978)Google Scholar
  13. T. J. Crow: Molecular pathology of schizophrenia: more than one disease process. Br Med J 6207:66–68 (1980)CrossRefGoogle Scholar
  14. T. Eibl-Eiblsfeld: Elternhaltung, psychophysiologische Erregung und Rückfallquote bei schizophrenen Patienten. Diss, vor der med. Fakultät der LMU München, 1983.Google Scholar
  15. Groß : Presynaptic alpha-adrenergic neurones. Nauyn-Schmiedebergfs Arch Pharmacol Sppl 313:387 (1980)Google Scholar
  16. Katschig : Sozialer Stress und psychische Krankheit. In: Fortschritte der Sozialpsychiatrie, Vol 5. Urban und Schwarzenberg, München (1978)Google Scholar
  17. R. E. Kendell: Waht are our criteria for a diagnosis of schizophrenia? In: H.M. van Praag (ed.). On the origin of schizophrenic psychoses. E Evven Bohn BV, Amsterdam (1975)Google Scholar
  18. CH. Lake, M. Ziegler, I. Kopin: Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sciences 18, 1315–1326 (1976)PubMedCrossRefGoogle Scholar
  19. Y. Lecrubier and P. Douillet. In: N. Matussek et al., Noradrenalin plasma level after sulpiride and other antidepressants during rest and ergomety. In: N. Matussek and M. Ackenheil (eds.): Special aspects of psychopharmacology. Possible clinical significance of recent biochemical and pharmacological findings with ortho-methoxy-benzamides. Expansiom Scientifique Française, Paris (1983).Google Scholar
  20. S. Matthyse: Antipsychotic drug actions: a cue to the neuropathology of schizophrenia. Fed Proc, 200–205 (1973)Google Scholar
  21. N. Matussek, M. Ackenheil, M. Herz: The dependence of the Clonidine growth hormone test on alcohol drinking habits and the menstrual cycle. (Accepted for publication by Psychoneuroendocrinology, 1984)Google Scholar
  22. D. Naber, F. Müller-Spahn: Effects of long-term neuroleptic treatment on serum levels of prolactin, TSH, LH and norepinephine, alpha-adrenergic and dopaminergic receptor sensitivity. Relation to tardive dyskinesia, 1983.Google Scholar
  23. D. Naber, C. Finkbeiner, H. Fischer, K. Zander, M. Ackenheil: Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: Relations to psychopathology and extrapyramidal symptoms. Neuropsychobiology 6, 181–189 (1980)PubMedCrossRefGoogle Scholar
  24. D. Naber, M. Albus, F. Müller-Spahn, H. Bürke, D. Welter, M. Ackenheil, H. Hippius: ß-endorphin, Cortisol and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal. Psychopharm Bull 18, 224–226 (1982)Google Scholar
  25. D. Naber und D. Pickar: Endorphins in CSF and plasma of psychiatric patients. Arzneim Forsch 32, 877–878 (1982)Google Scholar
  26. D. Naber, U. Münch, J. Wissmann, R. Grosse, R. Ritt, D. Welter: Naloxone treatment for 5 days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist. Acta Psychiat Scand 67, 265–271 (1983)CrossRefGoogle Scholar
  27. G. N. Pandey, D. L. Garver, C. Tamminga, S. Ericksen, S.J. Ali, 3.M. Davis: Postsynaptic supersensitivity in schizophrenia. Am J Psychiat 134:518–522 (1977).PubMedGoogle Scholar
  28. J. Rotrosen, B. Angrist, S. Gershon, J. Paquin, L. Branchey, M. Oleshansky, F. Halpern, E. J. Sachar: Neuroendocrine effects of apomorphine: characterization of response pattern and application to schizophrenia research. Brit J Psychiat 135, 444–456 (1979)PubMedCrossRefGoogle Scholar
  29. N. Tarrier, C.E. Vaughn, M.H. Lader, J.P. Leff: Bodily reactions to people and events in schizophrenics. Archives of General Psychiatry, 36:311–315 (1979)PubMedCrossRefGoogle Scholar
  30. K. J. Zander, B. Fischer, R. Zimmer, M. Ackenheil: Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal. Psychopharmacology 73:43–47 (1981). (This publication will be published more detailed in “Der Nervenarzt” (1984).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • H. Hippius
    • 1
  • M. Ackenheil
    • 1
  1. 1.Psychiatric Clinic of the University of MunichGermany

Personalised recommendations